Results 241 to 250 of about 221,455 (333)

Increased anergic B cells and decreased antibody‐secreting cells during romiplostim treatment in patients with immune thrombocytopenia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Patients with immune thrombocytopenia (ITP) exhibit substantial heterogeneity in treatment responses. Approximately 30%–50% of patients maintain remission after discontinuation of thrombopoietin receptor agonists (TPO‐RA), suggesting immunomodulatory effects beyond enhanced thrombopoiesis.
Vivianne S. Nelson   +5 more
wiley   +1 more source

SENIOR‐IPI: An easily applicable prognostic index for first‐line large B‐cell lymphomas patients >80 years treated with curative intent

open access: yesBritish Journal of Haematology, EarlyView.
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen.
Sydney Dubois   +8 more
wiley   +1 more source

Warm autoimmune haemolytic anaemia in Taiwan: A population‐based study of epidemiology, treatment patterns, survival and healthcare utilisation (2017–2022)

open access: yesBritish Journal of Haematology, EarlyView.
Summary To describe the epidemiology, treatment patterns, overall survival (OS) and healthcare resource use among patients with warm autoimmune haemolytic anaemia (wAIHA) in Taiwan, adult patients with ≥1 diagnosis code for autoimmune haemolytic anaemia (AIHA) with record of wAIHA‐related treatments between 2017 and 2022 were retrospectively identified
Hsiao‐Wen Kao   +8 more
wiley   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa   +25 more
wiley   +1 more source

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

open access: yesBritish Journal of Haematology, EarlyView.
Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy